Rodman & Renshaw

Investors initially celebrated a mixed Q2 earnings report from Valeant Pharmaceuticals Intl Inc (NYSE: VRX) to the tune of a 7 percent Tuesday-morning pop for the stock. However, that enthusiasm quickly evaporated as the reality of yet another guidance cut and an uncertain future started to sink in...

Initiating coverage of Alimera Sciences Inc (NASDAQ: ALIM) at a Buy rating and a $4 price target, Rodman & Renshaw said it views the company's commercialized product lluvien, which is a fluocinolone acetonide intravitreal implant, is differentiated from other corticosteroid treatment options...

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced last week it has been issued three new patents from the U.S. Patent and Trademark Office. The first patent relates to the manufacturing method for TRULANCE (plecanatide) and the other two relate to formulations and methods of using Trulance for...

Following his Tuesday tweets regarding Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)’s stock pumping, TheStreet's Adam Feuerstein told Benzinga the instance is only one example of an enduring problem in the market. “This company is one of the worst biotech companies out there that has...

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced the filing of the supplemental New Drug Application for Trulance (plecanatide) in constipation-predominant irritable bowel syndrome. Trulance’s approval in IBSC “should be a matter of routine,” Rodman & Renshaw’s...

Data presented by Cytokinetics, Inc. (NASDAQ: CYTK) showed CK-107 has the ability to positively impact two different animal models of spinal muscular atrophy. Rodman & Renshaw’s Joseph Pantginis reiterated a Buy rating on the company, with a price target of $25. Positive Indications The...

Apple Inc. (NASDAQ: AAPL)'s iconic founder, the late Steve Jobs, was a visionary par excellence, a trailblazer, a thought leader, a great inventor, an excellent communicator, a marketing genius — one who changed the way we learn, communicate and listen to music. Just like the Bible vests on...

Rodman & Renshaw reiterated its Buy rating on Synergy Pharmaceuticals Inc (NASDAQ: SGYP), saying the company’s “best-in-class” safety profile should boost the commercial launch of Trulance for the treatment of chronic idiopathic constipation (CIC). Trulance “...

After market close on January 19, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) reported that it had achieved FDA approval for its lead drug, plecanatide, in constipation-predominant irritable bowel syndrome (IBS-C). Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on the...

On January 5, Gevo, Inc. (NASDAQ: GEVO) completed its previously announced 1-for-20 stock split needed to maintain the common stock listing on the NASDAQ Capital Markets exchange. Rodman & Renshaw’s Amit Dayal maintains a Buy rating on the company, while raising the price target from $4...

Rodman & Renshaw’s Raghuram Selvaraju believes the top-line data announced by Synergy Pharmaceuticals Inc (NASDAQ: SGYP) from the first pivotal trial for plecanatide in constipation-predominant irritable bowel syndrome (IBS-C) positions the pipeline candidate as a “potentially best-...

Last Friday, shares of Synergy Pharmaceuticals Inc (NASDAQ: SGYP) traded down 5.78 percent, even though the company made public positive data from its first of two Phase III trials for its clinical constipation-predominant irritable bowel syndrome (IBS-C) drug, plecanatide. On Monday, research...

After a tough year, shares of Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) have managed to rebound more than 29 percent in the last month, largely on the back of the announcement that the FDA had allowed it to pursue regulatory approval of its Ocular Bandage Gel (OBG) under the De Novo 510(k) pathway...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) reported its Q3 revenue and earnings short of expectations. The company’s sales could decline in 2017, partly due to competition from generic products, Rodman & Renshaw’s Raghuram Selvaraju said in a report. He downgraded the rating on...

Rodman & Renshaw has started coverage of Abraxas Petroleum Corp. (NASDAQ: AXAS) with a Buy rating and $3 price target on potential upside from Delaware Basin and Austin Chalk. In Ward County, Texas, Abraxas is now pursuing Wolfcamp and Bone Spring activity, at depths shallower than longtime...